Vitamin D in Ovarian Cancer Recurrence. Study Reference: Laboratory / Translational Study   Ovarian cancer often recurs with poor outcomes, making recurrence prevention a major research focus. Emerging evidence shows that platinum chemotherapy can trigger non-stem cancer cells to convert into chemoresistant stem cells,and relapse. Vitamin D limits this conversion. Chemo treatment exacerbates vitamin D deficiency. Since   20% of Australian women are already vitamin D deficient ( a figure rising significantly in winter), routine testing and supplementation offer a safe, accessible strategy to help limit resistance and reduce recurrence risk. Key Points Driver of Relapse: Platinum chemotherapy may change cancer cells into stem-like cells, causing chemoresistance. Targeted Mechanism: Vitamin D  acts as a brake on this process, helping maintain chemotherapy sensitivity. Common Deficiency: About 1 in 5 Australian women are vitamin D deficient, with higher rates during ...

Therapeutic Vaccines for Ovarian Cancer: Is Clinical Reality Close? Study Reference: Systematic Review / Clinical Trial Analysis   The prospect of therapeutic vaccine therapy for ovarian cancer has generated interest for decades; such vaccines function by mobilising a targeted immune response against specific tumour antigens. While platforms using DNA, mRNA, peptides, and dendritic cells have streamlined vaccine manufacturing, clinical progress remains largely exploratory. A comprehensive review of 136 registered trials shows that over 90% remain in early Phase I or II, and no therapeutic vaccine has yet demonstrated clinical efficacy in Phase III trials. Consequently, current clinical development is shifting toward combination strategies (such as targeted antibody-drug conjugates) to overcome immune suppression. Key Points Exploratory Stage: Three  decades of research show that most therapeutic vaccine trials for ovarian cancer remain limited to early safety and immunogenici...

Dementia Prevention in Ovarian Cancer Care Study Reference: Clinical Guideline / Review | JAMA (2026) | DOI: 10.1001/jama.2026.2853908 Ovarian cancer is predominantly a disease of older women, a demographic facing a significant parallel health burden: for women aged 55 and over, the lifetime risk of developing dementia is 42%. With over 500,000 individuals currently living with dementia in Australia and no cure available, preventative health measures are paramount. Emerging evidence indicates that up to 45% of dementia cases could be prevented or delayed by addressing modifiable risk factors. For support nurses guiding women through ovarian cancer treatment and survivorship, integrating discussions on cardiovascular health, sensory management, and social engagement offers a vital opportunity to protect long-term cognitive health. Key Points High Lifetime Risk in Older Women: Women aged 55 or older face a 42% lifetime risk of dementia, with overall incidence rising alongside advancin...

Flavonoids in Ovarian Cancer Study Reference: The Journal of Steroid Biochemistry and Molecular Biology (2026) The Bottom Line When a diagnosis feels overwhelming, callers often reach for anything that offers a sense of control, frequently turning to natural substances, dietary supplements, and online "miracle cures." A recent scientific review looks at flavonoids, the natural compounds that give fruits and flowers their bright colours. While lab experiments show these molecules can target cancer cell pathways and potentially make tumours more sensitive to chemotherapy, translating science to human care is fraught with hurdles. Poor biological absorption and potential toxicities mean that taking high-dose supplements off the shelf can do more harm than good. Key Points Real Cellular Pathways: Flavonoids are not just hype; in cell cultures, they act through distinct molecular mechanisms to combat oxidative stress and dampen tumour-promoting inflammation. Chemosensitisation ...

New ASCO Guidelines for the Post-PARP Era in Recurrent Ovarian Cancer Study Reference: Journal of Clinical Oncology (2026)   The Bottom Line There are new guidelines for managing recurrent ovarian cancer, prompted by the widespread adoption of front-line PARP inhibitor (PARPi) maintenance, which has fundamentally altered how recurrences behave. Ovarian cancer following PARPi therapy often regains DNA repair capability, making traditional platinum-based cytotoxic chemotherapies far less effective, with consequent limited expectation of survival. The guidelines now suggest testing for Folate Receptor Alpha (FR-alpha) to identify the one-third of patients who would benefit from combination Antibody/drug therapy (ADC). The guidelines emphasise clinical trial enrolment alongside holistic care discussions, including early integration of palliative care. Key Points Realistic Prognostic Framing & Palliative Care: The guidelines emphasise introducing supportive care early to manage s...

Why Age 70+ Shouldn't Rule Out Genetic Testing Study Reference: Gynecologic Oncology | Retrospective Registry Study  The Bottom Line Ovarian cancer is predominantly a disease of older adults, yet women aged 70 and older are far less likely to receive germline genetic testing. This study of over 113,000 patients reveals that 6.6% of patients aged 70+ carry actionable, high-risk genetic mutations . Older women were 1.5 times less likely to report a family history of cancer . Relying on family history to decide who gets genetic testing in this age group leaves a significant number of mutation carriers unidentified, missing crucial opportunities for targeted therapies and family screening. Key Findings at a Glance Significant Mutation Rate: While overall variant rates decrease with age, nearly 1 in 15 women aged 70+ with ovarian cancer still carries an actionable germline mutation. Family History Unreliable: Older patients are significantly less likely to have a documented family ...